Fig. 2
MUC20 levels are predictive of proteasome inhibitor sensitivity and outcome of MM patients. A Analysis of the ORR and PD in patients with MM with high and low MUC20 expression after BTZ treatment. B Kaplan–Meier survival analysis of PFS and OS in patients with MM with high and low MUC20 expression. C Analysis of ORR and PD in patients with MM with high and low MUC20 expression after dexamethasone treatment. D Kaplan–Meier survival analysis of PFS and OS in patients with MM high and low MUC20 expression after dexamethasone treatment. E Analysis of the ORR and PD in patients with NDMM with high and low MUC20 expression after BTZ treatment. F Kaplan–Meier survival analysis of the PFS and OS in patients with NDMM with high and low MUC20 expression after BTZ treatment. BTZ: bortezomib; ORR: overall response rate; PD: progressive disease; PFS: progression free survival; OS: overall survival